Alpha Biopharma

Based in Shanghai, China, Alpha Biopharma is a biopharmaceutical company that develops innovative therapies targeting critical health challenges, primarily in oncology and infectious diseases. Alpha Biopharma, founded in 2018, focuses on the development of biopharmaceutical products. The company is headquartered in Shanghai, China. The founder has a background in creating healthcare solutions, though specific prior ventures are not mentioned.

In June 2018, Alpha Biopharma raised USD 65 mn in Series A funding, led by Qiming Venture Partners with participation from other investors. This round of funding was the company's sole investment target, supporting its strategic initiatives. 晨泰医药 (Chentai Pharmaceuticals) specializes in the development and manufacture of innovative biopharmaceutical products addressing critical health issues. Their offerings encompass therapeutics for oncology, infectious diseases, and chronic conditions, utilizing advanced biotechnological processes to enhance efficacy and safety.

Chentai Pharmaceuticals provides solutions to hospitals, healthcare providers, and research institutions primarily across North America, Europe, and Asia Pacific, focusing on research and development to meet evolving patient needs. Chentai Pharmaceuticals generates its revenue through a structured business model that involves direct sales and partnerships with healthcare organizations. Their transactions are primarily B2B, with hospitals and clinics purchasing their proprietary therapies aimed at specific diseases. Pricing strategies are tailored to reflect the value of these therapies, and the company may engage in collaborative partnerships, sharing revenues from joint development projects or co-marketing agreements.

Following the USD 65 mn raised in Series A funding in June 2018, Alpha Biopharma aims to conduct an international multi-center Phase II clinical trial for their product AZD3759, while also enriching their product pipeline. The company plans to expand its market presence beyond current regions, focusing on potential new markets throughout Asia Pacific and Europe by 2025, leveraging the recent funding to support these initiatives.